Finally, we believe that these protein signatures regulated by PAX3-FOXO1 will help to elucidate the malignant progression of ARMS with PAX3-FOXO1 fusion and lead to the development of novel therapeutic strategies. This evidence concerns the gene FOXO1 and alveolar rhabdomyosarcoma.